301239 普瑞眼科
已收盘 03-03 15:00:00
资讯
新帖
简况
普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押395万股，占总股本2.64%
证券之星 · 03-02 18:34
普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押395万股，占总股本2.64%
股市必读：普瑞眼科（301239）预计2025年全年营业收入27.5亿元至28.5亿元
证券之星 · 02-02
股市必读：普瑞眼科（301239）预计2025年全年营业收入27.5亿元至28.5亿元
普瑞眼科（301239）披露2025年度业绩预告，1月30日股价下跌2.7%
证券之星 · 01-30
普瑞眼科（301239）披露2025年度业绩预告，1月30日股价下跌2.7%
股市必读：普瑞眼科（301239）1月20日董秘有最新回复
证券之星 · 01-21
股市必读：普瑞眼科（301239）1月20日董秘有最新回复
普瑞眼科：新医院尚未整体进入业绩释放期
证券之星 · 01-20
普瑞眼科：新医院尚未整体进入业绩释放期
股市必读：普瑞眼科（301239）1月16日董秘有最新回复
证券之星 · 01-19
股市必读：普瑞眼科（301239）1月16日董秘有最新回复
普瑞眼科：公司若触发业绩预告披露情形将依规披露
证券之星 · 01-16
普瑞眼科：公司若触发业绩预告披露情形将依规披露
普瑞眼科（301239）披露注销部分募集资金专项账户，1月14日股价上涨0.59%
证券之星 · 01-14
普瑞眼科（301239）披露注销部分募集资金专项账户，1月14日股价上涨0.59%
每周股票复盘：普瑞眼科（301239）开展2025年度持续督导培训
证券之星 · 01-03
每周股票复盘：普瑞眼科（301239）开展2025年度持续督导培训
12月31日普瑞眼科涨6.23%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 2025-12-31
12月31日普瑞眼科涨6.23%，融通健康产业灵活配置混合A/B基金重仓该股
11月21日普瑞眼科跌6.15%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 2025-11-21
11月21日普瑞眼科跌6.15%，融通健康产业灵活配置混合A/B基金重仓该股
普瑞眼科（301239）2025年三季报简析：营收净利润同比双双增长
证券之星 · 2025-10-29
普瑞眼科（301239）2025年三季报简析：营收净利润同比双双增长
普瑞眼科(301239)9月30日股东户数1.04万户，较上期减少1.98%
证券之星 · 2025-10-27
普瑞眼科(301239)9月30日股东户数1.04万户，较上期减少1.98%
普瑞眼科(301239.SZ)发布前三季度业绩，归母净利润1634.91万元，增长3.21%
智通财经 · 2025-10-27
普瑞眼科(301239.SZ)发布前三季度业绩，归母净利润1634.91万元，增长3.21%
普瑞眼科（301239）披露董事会成员调整及换届选举议案，10月17日股价下跌1.14%
证券之星 · 2025-10-17
普瑞眼科（301239）披露董事会成员调整及换届选举议案，10月17日股价下跌1.14%
普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押190万股，占总股本1.27%
证券之星 · 2025-09-29
普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押190万股，占总股本1.27%
普瑞眼科（301239）发布2025年半年度持续督导跟踪报告，9月17日股价下跌0.28%
证券之星 · 2025-09-17
普瑞眼科（301239）发布2025年半年度持续督导跟踪报告，9月17日股价下跌0.28%
股市必读：普瑞眼科（301239）9月10日董秘有最新回复
证券之星 · 2025-09-11
股市必读：普瑞眼科（301239）9月10日董秘有最新回复
普瑞眼科：二季度受需求放缓及行业竞争影响业绩下滑
证券之星 · 2025-09-10
普瑞眼科：二季度受需求放缓及行业竞争影响业绩下滑
3月7日普瑞眼科跌5.97%，广发高端制造股票A基金重仓该股
证券之星 · 2025-03-07
3月7日普瑞眼科跌5.97%，广发高端制造股票A基金重仓该股
加载更多
公司概况
公司名称：
普瑞眼科医院集团股份有限公司
所属行业：
卫生
上市日期：
2022-07-05
主营业务：
普瑞眼科医院集团股份有限公司的主营业务是为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。公司的主要产品是屈光手术、白内障、眼视光、眼底病、青光眼、斜视与小儿眼科、泪道、角膜病、眼眶病、眼外伤、医学验光配镜。
发行价格：
33.65
{"stockData":{"symbol":"301239","market":"SZ","secType":"STK","nameCN":"普瑞眼科","latestPrice":31.23,"timestamp":1772521386000,"preClose":31.8,"halted":0,"volume":1555462,"delay":0,"changeRate":-0.0179,"floatShares":150000000,"shares":150000000,"eps":-0.6775,"marketStatus":"已收盘","change":-0.57,"latestTime":"03-03 15:00:00","open":31.8,"high":32.2,"low":31.2,"amount":49228300,"amplitude":0.0314,"askPrice":31.24,"askSize":7,"bidPrice":31.23,"bidSize":38,"shortable":0,"etf":0,"ttmEps":-0.6775,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772587800000},"marketStatusCode":5,"adr":0,"adjPreClose":31.8,"symbolType":"stock","openAndCloseTimeList":[[1772501400000,1772508600000],[1772514000000,1772521200000]],"highLimit":34.98,"lowLimit":28.62,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":149619048,"isCdr":false,"pbRate":2.24,"roa":"--","roe":"0.77%","epsLYR":-0.68,"committee":0.251142,"marketValue":4673000000,"turnoverRate":0.0104,"status":1,"floatMarketCap":4673000000},"requestUrl":"/m/hq/s/301239","defaultTab":"news","newsList":[{"id":"2616333961","title":"普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押395万股，占总股本2.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333961","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616333961?lang=zh_cn&edition=full","pubTime":"2026-03-02 18:34","pubTimestamp":1772447694,"startTime":"0","endTime":"0","summary":"证券之星消息，普瑞眼科3月2日公开信息显示，股东成都普瑞世纪投资有限责任公司向中原信托有限公司合计质押395.0万股，占总股本2.64%。质押详情见下表：截止本公告日，股东成都普瑞世纪投资有限责任公司已累计质押股份3073.12万股，占其持股总数的57.2%。普瑞眼科主营业务：致力于为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200030276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2608881633","title":"股市必读：普瑞眼科（301239）预计2025年全年营业收入27.5亿元至28.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608881633","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608881633?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:28","pubTimestamp":1769977689,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，普瑞眼科报收于34.65元，下跌2.7%，换手率1.12%，成交量1.67万手，成交额5845.12万元。业绩披露要点业绩预告普瑞眼科发布业绩预告，预计2025年全年扣非后净利润亏损3700万元至5200万元；预计2025年全年营业收入27.5亿元至28.5亿元；预计2025年全年归属净利润亏损5000万元至6900万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239"],"gpt_icon":0},{"id":"2607042608","title":"普瑞眼科（301239）披露2025年度业绩预告，1月30日股价下跌2.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042608","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607042608?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:23","pubTimestamp":1769786593,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，普瑞眼科报收于34.65元，较前一交易日下跌2.7%，最新总市值为51.84亿元。该股当日开盘35.35元，最高35.85元，最低34.35元，成交额达5845.12万元，换手率为1.12%。普瑞眼科于近日披露《2025年度业绩预告》。公告显示，公司预计2025年度归属于上市公司股东的净利润为-6,900万元至-5,000万元，扣除非经常性损益后的净利润为-5,200万元至-3,700万元，较上年同期亏损收窄；营业收入预计为27.5亿元至28.5亿元，同比增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2605414374","title":"股市必读：普瑞眼科（301239）1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605414374?lang=zh_cn&edition=full","pubTime":"2026-01-21 02:43","pubTimestamp":1768934588,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，普瑞眼科报收于33.67元，下跌0.59%，换手率0.81%，成交量1.21万手，成交额4079.55万元。董秘最新回复投资者： 董秘您好，非常支持并理解公司的扩张经营进取策略，做为持有者非常想了解近年新开医院的近况。根据公司公开信息，2023-2025年间新增了12家医院。公司在新建医院前均经过审慎评估与规划。当日关注点来自交易信息汇总：1月20日主力资金净流出585.54万元，显示主力短期谨慎态度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100001155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2604162946","title":"普瑞眼科：新医院尚未整体进入业绩释放期","url":"https://stock-news.laohu8.com/highlight/detail?id=2604162946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604162946?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:04","pubTimestamp":1768892658,"startTime":"0","endTime":"0","summary":"请问从管理角度看，这些新院25年是否已整体进入业绩释放期？公司近年新开设的医院目前仍处于市场培育和收入爬坡阶段，尚未整体进入业绩释放期，这一发展节奏符合民营医院行业的普遍规律，也与公司的预期基本一致。为科学评估新医院的经营进展，公司已建立一套多维度的运营考核体系，我们重点关注门诊量、手术量、营业收入等成长性指标，同时也会动态监测业务结构优化与净利润改善等情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000017996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2604972548","title":"股市必读：普瑞眼科（301239）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604972548","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604972548?lang=zh_cn&edition=full","pubTime":"2026-01-19 04:12","pubTimestamp":1768767130,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，普瑞眼科报收于33.85元，下跌1.37%，换手率0.99%，成交量1.48万手，成交额5020.58万元。公司股价受市场多重因素影响，我们实时关注股价波动并始终重视投资者的回报。公司若触发业绩预告披露情形，将在会计年度结束后1个月内依规披露；未触发则无需披露。当日关注点来自交易信息汇总：1月16日主力资金净流出106.58万元，显示主力小幅减持动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900001568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2603956412","title":"普瑞眼科：公司若触发业绩预告披露情形将依规披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2603956412","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603956412?lang=zh_cn&edition=full","pubTime":"2026-01-16 11:36","pubTimestamp":1768534578,"startTime":"0","endTime":"0","summary":"证券之星消息，普瑞眼科01月16日在投资者关系平台上答复投资者关心的问题。公司股价受市场多重因素影响，我们实时关注股价波动并始终重视投资者的回报。公司若触发业绩预告披露情形，将在会计年度结束后1个月内依规披露；未触发则无需披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600015387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2603612993","title":"普瑞眼科（301239）披露注销部分募集资金专项账户，1月14日股价上涨0.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603612993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603612993?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:37","pubTimestamp":1768401430,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，普瑞眼科报收于34.26元，较前一交易日上涨0.59%，最新总市值为51.26亿元。该股当日开盘33.99元，最高35.1元，最低33.61元，成交额达1.02亿元，换手率为1.98%。截至公告日，上述账户注销手续已完成，对应的监管协议终止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2600928067","title":"每周股票复盘：普瑞眼科（301239）开展2025年度持续督导培训","url":"https://stock-news.laohu8.com/highlight/detail?id=2600928067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600928067?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:50","pubTimestamp":1767379817,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，普瑞眼科报收于32.89元，较上周的31.22元上涨5.35%。本周，普瑞眼科12月31日盘中最高价报34.1元。12月30日盘中最低价报30.75元。普瑞眼科当前最新总市值49.21亿元，在医疗服务板块市值排名34/51，在两市A股市值排名3399/5181。公司公告汇总国泰海通证券股份有限公司作为普瑞眼科医院集团股份有限公司的保荐机构，于2025年12月22日以现场与线上相结合的方式开展了2025年度持续督导培训。公司对本次培训积极配合，达到了预期效果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2595805721","title":"12月31日普瑞眼科涨6.23%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595805721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595805721?lang=zh_cn&edition=full","pubTime":"2025-12-31 15:36","pubTimestamp":1767166603,"startTime":"0","endTime":"0","summary":"证券之星消息，12月31日普瑞眼科涨6.23%，收盘报32.89元，换手率3.52%，成交量5.26万手，成交额1.73亿元。重仓普瑞眼科的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家；过去90天内机构目标均价为42.05。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100022392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2585190059","title":"11月21日普瑞眼科跌6.15%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190059?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:05","pubTimestamp":1763712311,"startTime":"0","endTime":"0","summary":"证券之星消息，11月21日普瑞眼科跌6.15%创60日新低，收盘报33.85元，换手率1.87%，成交量2.8万手，成交额9690.99万元。重仓普瑞眼科的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级2家，增持评级2家；过去90天内机构目标均价为48.4。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100019189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2579164679","title":"普瑞眼科（301239）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2579164679","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579164679?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:44","pubTimestamp":1761691481,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期普瑞眼科发布2025年三季报。根据财报显示，普瑞眼科营收净利润同比双双增长。截至本报告期末，公司营业总收入22.01亿元，同比上升2.99%，归母净利润1634.91万元，同比上升3.21%。按单季度数据看，第三季度营业总收入7.41亿元，同比上升3.48%，第三季度归母净利润168.17万元，同比上升106.13%。持有普瑞眼科最多的基金为融通健康产业灵活配置混合A/B，目前规模为18.16亿元，最新净值2.819，较上一交易日下跌0.04%，近一年上涨10.11%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900010963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239"],"gpt_icon":0},{"id":"2578164006","title":"普瑞眼科(301239)9月30日股东户数1.04万户，较上期减少1.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578164006","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578164006?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:17","pubTimestamp":1761556638,"startTime":"0","endTime":"0","summary":"证券之星消息，近日普瑞眼科披露，截至2025年9月30日公司股东户数为1.04万户，较6月30日减少211.0户，减幅为1.98%。在医疗服务行业个股中，普瑞眼科股东户数低于行业平均水平，截至9月30日，医疗服务行业平均股东户数为4.63万户。从股价来看，2025年6月30日至2025年9月30日，普瑞眼科区间跌幅为6.63%，在此期间股东户数减少211.0户，减幅为1.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700023664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2578618554","title":"普瑞眼科(301239.SZ)发布前三季度业绩，归母净利润1634.91万元，增长3.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578618554","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578618554?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:10","pubTimestamp":1761552600,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普瑞眼科(301239.SZ)发布2025年三季度报告，该公司前三季度营业收入为22.01亿元，同比增长2.99%。归属于上市公司股东的净利润为1634.91万元，同比增长3.21%。归属于上市公司股东的扣除非经常性损益的净利润为2466.98万元，同比增长34.71%。基本每股收益为0.11元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301239"],"gpt_icon":0},{"id":"2576514900","title":"普瑞眼科（301239）披露董事会成员调整及换届选举议案，10月17日股价下跌1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576514900","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576514900?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:50","pubTimestamp":1760712626,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，普瑞眼科报收于36.31元，较前一交易日下跌1.14%，最新总市值为54.33亿元。该股当日开盘36.73元，最高36.88元，最低36.3元，成交额达3124.01万元，换手率为0.57%。上述选举议案均需提交股东会采用累积投票制表决。所有议案表决结果均为同意7票，反对0票，弃权0票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700038774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2571849483","title":"普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押190万股，占总股本1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571849483","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571849483?lang=zh_cn&edition=full","pubTime":"2025-09-29 18:28","pubTimestamp":1759141709,"startTime":"0","endTime":"0","summary":"证券之星消息，普瑞眼科9月29日公开信息显示，股东成都普瑞世纪投资有限责任公司向杭州银行股份有限公司上海张江支行合计质押190.0万股，占总股本1.27%。质押详情见下表：截止本公告日，股东成都普瑞世纪投资有限责任公司已累计质押股份2494.12万股，占其持股总数的46.42%。普瑞眼科主营业务：致力于为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900028040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2568497680","title":"普瑞眼科（301239）发布2025年半年度持续督导跟踪报告，9月17日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568497680","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568497680?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:48","pubTimestamp":1758120497,"startTime":"0","endTime":"0","summary":"截至2025年9月17日收盘，普瑞眼科报收于38.87元，较前一交易日下跌0.28%，最新总市值为58.16亿元。近日，国泰海通证券股份有限公司发布了关于普瑞眼科医院集团股份有限公司2025年半年度持续督导跟踪报告（报备）。公告显示，报告期内，保荐人及时审阅信息披露文件，公司信息披露规范，未发生未及时审阅情况。报告期内发表专项意见6次，无非同意意见，公司及相关股东均正常履行承诺事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700040673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2566348987","title":"股市必读：普瑞眼科（301239）9月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2566348987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566348987?lang=zh_cn&edition=full","pubTime":"2025-09-11 04:46","pubTimestamp":1757537172,"startTime":"0","endTime":"0","summary":"截至2025年9月10日收盘，普瑞眼科报收于38.1元，上涨0.32%，换手率1.04%，成交量1.56万手，成交额5948.98万元。董秘最新回复投资者： 公司一季度业绩有所好转，录得扣非净利润 2,831.55 万元，同比增长48.37%，经营活动现金流净额 1.95 亿元，同比增长 54.87%，整体呈现营收、利润、现金流协同增长的良好态势。当日关注点来自交易信息汇总：9月10日主力资金净流出48.2万元，游资积极介入，散户同步减持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100003919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2566626006","title":"普瑞眼科：二季度受需求放缓及行业竞争影响业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2566626006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566626006?lang=zh_cn&edition=full","pubTime":"2025-09-10 11:36","pubTimestamp":1757475412,"startTime":"0","endTime":"0","summary":"但半年报发布后，我们发现二季度业绩下滑明显，甚至抹去了一季度的部分利润。普瑞眼科回复：尊敬的投资者您好，2025年二季度受整体需求增长放缓及行业竞争加剧的双重影响，公司各业务板块的营收增长受到较大挑战，且白内障项目受人工晶体集中带量采购政策及医保DRG/DIP支付方式改革等影响，营业收入下降，故二季度整体业绩有所下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000015003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2517170897","title":"3月7日普瑞眼科跌5.97%，广发高端制造股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517170897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517170897?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:25","pubTimestamp":1741335959,"startTime":"0","endTime":"0","summary":"证券之星消息，3月7日普瑞眼科跌5.97%，收盘报49.9元，换手率4.34%，成交量3.07万手，成交额1.56亿元。根据2024基金年报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为广发高端制造股票A。广发高端制造股票A目前规模为61.43亿元，最新净值1.2707，较上一交易日上涨0.89%，近一年下跌13.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700026706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161037","BK0236","301239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772550847016,"stockEarnings":[{"period":"1week","weight":-0.045},{"period":"1month","weight":-0.0823},{"period":"3month","weight":-0.0567},{"period":"6month","weight":-0.1632},{"period":"1year","weight":-0.3919},{"period":"ytd","weight":-0.0331}],"compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":0.0157},{"period":"3month","weight":0.0731},{"period":"6month","weight":0.0968},{"period":"1year","weight":0.2595},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"普瑞眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"10438人(较上一季度减少1.98%)","perCapita":"14334股","listingDate":"2022-07-05","address":"四川省成都市金牛区一环路北四段215号","registeredCapital":"14961万元","survey":" 普瑞眼科医院集团股份有限公司的主营业务是为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。公司的主要产品是屈光手术、白内障、眼视光、眼底病、青光眼、斜视与小儿眼科、泪道、角膜病、眼眶病、眼外伤、医学验光配镜。","listedPrice":33.65},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普瑞眼科(301239)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普瑞眼科(301239)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普瑞眼科,301239,普瑞眼科股票,普瑞眼科股票老虎,普瑞眼科股票老虎国际,普瑞眼科行情,普瑞眼科股票行情,普瑞眼科股价,普瑞眼科股市,普瑞眼科股票价格,普瑞眼科股票交易,普瑞眼科股票购买,普瑞眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普瑞眼科(301239)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普瑞眼科(301239)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}